JHJianjing Hou

Jianjing Hou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jianjing Hou has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Jiong Wu

    Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai Fudan University Shanghai Cancer Center Shanghai China

    3 shared publications
  • Bingqiu Xiu

    Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China

    1 shared publication
  • Changming Zhou

    Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai, China

    1 shared publication
  • Genhong Di

    Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

    1 shared publication
  • Guangyu Liu

    Fudan University Shanghai Cancer Center, Shanghai, China

    1 shared publication
  • Jia Wang

    Department of Breast Surgery,Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Protocol for a multicentre, prospective, open-label, randomised controlled trial to compare PROs and safety outcomes between preoperative and postmastectomy radiotherapy in locally advanced breast cancer patients with immediate reconstruction via a deep inferior epigastric perforator flap (CAPPELLA) in China

    by Shuang Hao, Jianjing Hou, Li Zhang, Changming Zhou, Yifeng Hou, Keda Yu, Zhen Hu, Guangyu Liu, Genhong Di, Zhi Min Shao, et al.

    Introduction Despite its therapeutic advantages, postmastectomy radiotherapy (PMRT) increases the risk of complications and often leads to poor cosmesis in women undergoing breast reconstruction. Preoperative radiotherapy followed by skin-sparing mastectomy and deep inferior epigastric perforator (DIEP) flap reconstruction is technically feasible, with low rates of surgical complications and good short-term oncological outcomes. Further evaluation in a randomised trial comparing preoperative radiotherapy versus conventional PMRT in breast reconstruction is required to assess both oncological and patient-reported outcomes (PROs). Methods and analysis The CAPPELLA trial is a prospective, multicentre, open-label, randomised controlled trial across nine centres comparing PROs and safety outcomes between preoperative and postoperative radiotherapy in patients with locally advanced breast cancer requiring immediate DIEP flap reconstruction. Female patients aged >18 years with breast cancer who are treated with neoadjuvant systemic treatment, require both mastectomy and radiotherapy and are suitable for DIEP flap reconstruction will be included. Patients will be randomly assigned (1:1) to a preoperative radiotherapy group or a postoperative radiotherapy group. Stratification will be performed by cancer centre at initial diagnosis. The radiation volumes will include the ipsilateral breast/chest wall, supraclavicular lymph nodes, undissected axilla and internal mammary nodes. The dose regimen will be 42.56 Gy in 16 fractions. The primary endpoint will be satisfaction with the breast domain of the BREAST-Q at 2 years postoperatively. The secondary endpoints will include PROs at 3, 12 and 24 months postoperatively in both groups, aesthetic assessment, complication rates, rates of total pathological complete response (tpCR) and tumour safety. All patients will be followed up for 36 months postoperatively. The app software will be used to collect all data prospectively. Data will be analysed using SPSS and Stata software. The target sample size will be 80 participants. Ethics and dissemination This study will be performed according to the Helsinki Declaration. All patients will be asked to provide informed consent before enrolment. Approval for this study was provided by the independent ethics committee and institutional review board of Fudan University Shanghai Cancer Centre. We will present the study results at national and international meetings and publish them in a scientific peer-reviewed journal. Trial registration number NCT05512286.


  • Open Access

    MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast Cancer

    by Weiru Chi, Bingqiu Xiu, Min Xiong, Xuliren Wang, Pei Li, Qi Zhang, Jianjing Hou, Yuting Sang, Xujie Zhou, Ming Chen, et al.

    Although targeted therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer has significantly prolonged survival time and improved patients’ quality of life, drug resistance has gradually emerged. This study explored the mechanisms underlying the effect of the motor neuron and pancreatic homeobox 1 (MNX1) genes on drug sensitivity in HER2-positive breast cancer. From July 2017 to 2018, core needle biopsies of HER2-positive breast cancer were collected from patients who received paclitaxel, carboplatin, and trastuzumab neoadjuvant therapy at our center. Based on treatment efficacy, 81 patients were divided into pathological complete response (pCR) and non-pCR groups. High-throughput RNA sequencing results were analyzed along with the GSE181574 dataset. MNX1 was significantly upregulated in the pCR group compared with the non-pCR group in both sequencing datasets, suggesting that MNX1 might be correlated with drug sensitivity in HER2-positive breast cancer. Meanwhile, tissue array results revealed that high MNX1 expression corresponded to a good prognosis. In vitro functional tests showed that upregulation of MNX1 significantly increased the sensitivity of HER2-positive breast cancer cells to lapatinib and pyrotinib. In conclusion, MNX1 may serve as a prognostic marker for patients with HER2-positive breast cancer, and its expression may facilitate clinical screening of patients sensitive to anti-HER2-targeted therapy.


  • Young age is associated with inferior outcomes in early-stage luminal B breast cancer patients who undergo mastectomy

    by Jianjing Hou, Lun Li, Jia Wang, Xiaoyan Huang, Jingyan Xue, Jiong Wu

    Background: This retrospective study aimed to evaluate the effect of age on cancer relapse and survival in breast cancer patients undergoing different treatments. Methods: The propensity score meth... Tweetable abstract Young age was an independent prognostic factor associated with poor prognosis in T1–2N0 patients undergoing mastectomy. More comprehensive monitoring and a biology-driven adjuvan...